Clinical efficacy of buprenorphine: comparisons to methadone and placebo
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Buprenorphine has been studied extensively since 1978 when it was initially proposed as an alternative to methadone for treatment of opioid dependence. Early work by Jasinski et al., 1978; Mello and Mendelson, 1980; Mello et al., 1982; Mello et al., 1983 and Mendelson et al., 1984 and their colleagues demonstrated buprenorphine's low physical abuse potential and its ability to substitute for heroin and reduce heroin self-administration in opiate-dependent humans. The subsequent early clinical studies suggested that, in clinical settings, buprenorphine was a safe and efficacious opiate dependence pharmacotherapy. Formal approval for general clinical use, however, required that systematic data be gathered on buprenorphine's safety and efficacy in larger groups and a series of controlled clinical trials was designed to evaluate its utility from a medication development perspective. In general, these trials adhered to one of three basic protocol designs: comparison of buprenorphine to methadone; dose comparisons using dose response as an indicator of efficacy; and comparison of buprenorphine to placebo. Retention in treatment, reduction in illicit drug use and craving, and patient and staff ratings of improvements were the most frequently used outcome indicators in these trials. Additional data collected included optimum dosing and dosage schedules, adverse reactions and common side-effects, and other information intended to clarify buprenorphine's benefit-risk relationship and to help prepare guidelines for its safe marketing and utilization by physicians in general clinical practice. This paper presents a review of the buprenorphine/methadone comparison trials conducted in the United States and two such trials conducted in Europe. Also reviewed are three placebo-controlled trials and a buprenorphine/methadone detoxification study. Overall, this series of studies did firmly establish the efficacy of buprenorphine alone and in comparison to methadone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Because of safety issues, buprenorphine/naloxone is the preferred formulation309, 310.”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [309]
In the citing paper
“Buprenorphine is the preferred treatment for opioid dependence, and appears to be safer than methadone.”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [309]
Citations
Cites
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480200058024 · Cited by 572
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
Self-citationA Controlled Trial Comparing Buprenorphine and Methadone Maintenance in Opioid Dependence
Ling, W. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050035005 · Cited by 366
Self-citationComparison of buprenorphine and methadone in the treatment of opioid dependence
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.1025 · Cited by 305
Buprenorphine vs Methadone Maintenance Treatment for Concurrent Opioid Dependence and Cocaine Abuse
Schottenfeld, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200041006 · Cited by 303
Buprenorphine suppresses heroin use by heroin addicts
Mello, N. K., & Mendelson, J. H. (1980) · Science · doi:10.1126/science.7352279 · Cited by 298
Buprenorphine versus Methadone Maintenance for Opioid Dependence
KOSTEN, T. R., SCHOTTENFELD, R., ZIEDONIS, D., & FALCIONI, J. (1993) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199306000-00004 · Cited by 267
Use of buprenorphine in pregnancy: patient management and effects on the neonate
JOHNSON, R. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00062-0 · Cited by 245
Cited by
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Babor, T. F., McRee, B. G., Kassebaum, P. A., Grimaldi, P. L., Ahmed, K., & Bray, J. (2007) · Substance Abuse · doi:10.1300/j465v28n03_03 · Cited by 1,100
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
Reynolds, C. F., Jeste, D. V., Sachdev, P. S., & Blazer, D. G. (2022) · World Psychiatry · doi:10.1002/wps.20996 · Cited by 465
Bliesener, N., Albrecht, S., Schwager, A., Weckbecker, K., Lichtermann, D., & Klingmüller, D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0929 · Cited by 236
Metadata
- Authors
- LING, W.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- LING, W
- ORCID
- LING, W
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2003-05
- Volume
- 70
- Issue
- 2
- Pages
- S49-S57
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2048376222
- Cited by
- 121
- References
- 18
- Citations by year
- 2024: 2 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 6 · 2019: 4 · 2018: 3 · 2016: 7 · 2015: 5 · 2014: 6 · 2013: 4 · 2012: 6
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Drug and Alcohol Dependence (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (DA09260, DA99004, P50DA012755, P50DA009260, DA12755)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- buprenorphine, methadone, opioid use disorder, opioid substitution therapy, heroin addiction, treatment retention, illicit drug use, craving, detoxification, dose-response relationship, adverse effects, risk-benefit ratio
- MeSH terms
- Buprenorphine, Humans, Methadone, Narcotic Antagonists, Opioid-Related Disorders, Placebos, Substance Withdrawal Syndrome, Controlled Clinical Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical efficacy of buprenorphine: comparisons to methadone and placebo. https://app.cochat.ai/papers/10.1016/s0376-8716(03)00059-0
- The paper
- LING, W. (2003). Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug and Alcohol Dependence. https://doi.org/10.1016/s0376-8716(03)00059-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.